You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HR /HER2 Breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)

Not yet recruiting
  • HR+/HER2- Breast Cancer
  • (no location specified)
Nov 21, 2022

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Breast Cancer Trial in Tianjin (Pyrrolidine?trastuzumab?AI)

Recruiting
  • Breast Cancer
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Jun 1, 2023

HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

Not yet recruiting
  • HR+/HER2-breast Cancer
  • Standard endocrine therapy plus Apatinib
  • (no location specified)
Jun 2, 2023

Breast Cancer Trial in Shantou (dose-dense nab-paclitaxel followed by EC)

Recruiting
  • Breast Cancer
  • dose-dense nab-paclitaxel followed by EC
  • Shantou, Guangdong, China
    Shantou Central Hospital
Feb 4, 2023

Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Recruiting
  • Breast Cancer
  • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Mar 23, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

Breast Cancer Trial in Ann Arbor (Ribociclib, Postoperative Radiation Therapy)

Not yet recruiting
  • Breast Cancer
  • Ann Arbor, Michigan
    University of Michigan
Aug 10, 2023

Breast Cancer Trial (dalpiciclib plus letrozole)

Not yet recruiting
  • Breast Cancer
  • dalpiciclib plus letrozole
  • (no location specified)
Aug 21, 2022

Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

Not yet recruiting
  • Breast Cancer
  • +3 more
  • (no location specified)
Aug 4, 2023

Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Washington, Baltimore, Hackensack

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Washington, District of Columbia
  • +4 more
Jan 31, 2023

Breast Cancer Trial (Patritumab deruxtecan, Chemotherapy, Letrozole)

Recruiting
  • Breast Cancer
  • Patritumab deruxtecan
  • +2 more
  • Barcelona, Spain
    Hospital Clinic de Barcelona
Nov 28, 2022

Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

Recruiting
  • Locally Advanced Breast Cancer
  • Hormone Receptor Positive，HER2-negative Breast Cancer
  • Jinan, Shandong, China
    Breast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023

Breast Cancer Trial in Lexington, East Syracuse (TOL2506, Tamoxifen, Letrozole tablets)

Enrolling by invitation
  • Breast Cancer
  • Lexington, Kentucky
  • +1 more
Jan 9, 2023

Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)

Recruiting
  • Brain Metastases
  • HR+ Metastatic Breast Cancer
  • Stereotactic Radiosurgery (SRS)
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Nov 1, 2022

Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Boston

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Boston, Massachusetts
  • +2 more
Nov 3, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Breast Cancer Trial in Limoges, Villejuif (Anti-aromatase inhibitor)

Not yet recruiting
  • Breast Cancer
  • Anti-aromatase inhibitor
  • Limoges, France
  • +1 more
Jul 25, 2022

Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)

Recruiting
  • Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023

Prosigna Assay on Neoadjuvant Clinical Decision-making in

Recruiting
  • Breast Cancer
  • Prosigna PAM-50 assay
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Apr 5, 2022

Breast Cancer Trial in Aurora, Durham, Spokane Valley (Abemaciclib, Elacestrant)

Recruiting
  • Breast Cancer
  • Aurora, Colorado
  • +2 more
May 10, 2022

Luminal Metastatic breAst caNcer in Real-life Clinical pracTice

Completed
  • HR+/HER2- Breast Cancer
  • +2 more
  • Moscow, Russian Federation
    Russian Society of Clinical Oncology
Mar 29, 2023

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

Active, not recruiting
  • Hormone-receptor-positive Breast Cancer
  • +2 more
  • No drug
  • Cambridge, Massachusetts
    ConcertAI database
Sep 8, 2023